|
Market Closed -
Nasdaq
21:00:00 01/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 4.540 USD | -2.37% |
|
-13.36% | -92.06% |
| 09-17 | Immutep refocuses efti development on head and neck cancer and soft tissue sarcoma | FI |
| 09-15 | Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 74.46B | |||||
| 60.14B | |||||
| 48.15B | |||||
| 44.25B | |||||
| 43.99B | - | - | - | - | - |
Select your edition
All financial news and data tailored to specific country editions
